Treatment Strategy for Inadequate Antidepressant Response

Introduction to Treatment Strategies

The American College of Physicians suggests that both switching antidepressants and augmenting with atypical antipsychotics show similar efficacy for treatment-resistant depression, but the evidence shows no clear superiority of one strategy over the other 1, 2, 3, 4, 5.

Moderate-quality evidence shows no difference in response or remission rates when switching from one second-generation antidepressant to another (bupropion vs. sertraline vs. venlafaxine) 1, 2, 3, 4, 5.
Switching antidepressants is recommended if the current antidepressant is poorly tolerated or causing significant adverse effects (sexual dysfunction, weight gain, sedation), as switching allows you to select an agent with a more favorable side effect profile 6, 7, 8.
Switching antidepressants is recommended if there has been minimal or no response after 6-8 weeks of adequate dosing, particularly if this is the first antidepressant trial 6, 7, 8.
Consider augmentation if the patient has had partial response to the current antidepressant, as this suggests the medication has some benefit worth building upon 1, 2, 3, 4, 5.

Low-quality evidence shows no difference in response or remission between augmenting with another antidepressant versus switching to a different antidepressant 1, 2, 3, 4, 5.
Augmentation with bupropion decreases depression severity more than buspirone augmentation, though both show similar response and remission rates 1, 2, 3, 4, 5.
Switching to cognitive therapy shows no difference compared to switching antidepressants, providing another alternative if pharmacotherapy has been inadequate 1, 2, 4, 5.

Switching antidepressants avoids polypharmacy and the additive side effect burden of multiple medications 6, 7, 8.

Ensure adequate trial duration (6-8 weeks) and dosing before declaring treatment failure, as premature switching or augmentation may miss delayed response 6, 7, 8.
Monitor closely for suicidal ideation within 1-2 weeks of any medication change, as risk increases during treatment transitions 6, 7, 8.
Discontinuation rates due to adverse events are lower with bupropion augmentation compared to buspirone (moderate-quality evidence) 1, 2, 3, 4, 5.

If the patient has had minimal response, switch to a different antidepressant class 6, 7, 8.
If tolerability is the primary issue, switch to an antidepressant with a different side effect profile (e.g., bupropion for sexual dysfunction, mirtazapine for insomnia) 6, 7, 8.